Cyclin D1 and Chemotherapy Response
Abstract
Keywords
DOI: 10.33371/ijoc.v15i1.782
Article Metrics
Abstract View: 512,PDF Download: 312
References
Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Magliulo G, Presutti L, Re M. The prognostic value of cyclin d1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016 Apr;273(4):801-9.
Li Y, Barbash O, DIehl J. Regulation of the cell cycle. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson C, editors. The molecular basis of cancer. Edition 4 ed. Philadelphia, PA: Saunders/Elsevier; 2015. p. 165-78.
Dhingra V, Verma J, Misra V, Srivastav S, Hasan F. Evaluation of cyclin d1 expression in head and neck squamous cell carcinoma. J Clin Diagn Res. 2017 Feb;11(2):EC01-EC4.
Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin d1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report. Acta Oncol. 2001;40(4):505-11.
Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. Ccnd1/cyclind1 status in metastasizing bladder cancer: A prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014 Jan;27(1):87-95.
Ngo BT, Felthaus J, Hein M, Follo M, Wider D, Ihorst G, et al. Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin d1, d2, and d3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma. 2010 Sep;51(9):1632-42.
Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, et al. The association of ccnd1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010 Jun;176(6):2607-15.
Biliran H, Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin d1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005 Aug 15;11(16):6075-86.
Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, et al. Progress with palbociclib in breast cancer: Latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin d1: Normal and abnormal functions. Endocrinology. 2004 Dec;145(12):5439-47.
Qie S, Diehl JA. Cyclin d1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016 Dec;94(12):1313-26.
Li Y, Barbash O, DIehl JA. Regulation of the cell cycle. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, editors. The molecular basis of cancer. Philadeplphia: Elsevier; 2015. p. 165-78.
Boehm M, Nabel EG. Cell cycle and cell migration: New pieces to the puzzle. Circulation. 2001 Jun 19;103(24):2879-81.
Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, et al. Ccnd1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One. 2011;6(10):e26399.
Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014 Jan;124(1):179-87.
Moreno-Galindo C, Hermsen M, Garcia-Pedrero JM, Fresno MF, Suarez C, Rodrigo JP. P27 and bcl2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014 Feb;50(2):128-34.
Irawan C, Cahyanur R, Lisnawati L, Abdullah M, Yunus RE. The difference in the cyclin d1 expression in advanced stage nasopharyngeal cancer based on treatment response: A retrospective cohort study. Acta Med Indones. 2020 Apr;52(2):147-54.
Kornmann M, Beger HG, Link KH. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res. 2003;161:180-95.
Jirawatnotai S, Hu Y, Livingston DM, Sicinski P. Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 2012 Sep 1;72(17):4289-93.
Sewify EM, Afifi OA, Mosad E, Zaki AH, El Gammal SA. Cyclin d1 amplification in multiple myeloma is associated with multidrug resistance expression. Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):215-22.
Mohanty S, Tran T, Sandoval N, Mohanty A, Bedell V, Wu J, et al. Cyclin d1 promotes survival and chemoresistance by maintaining atr and chek1 signaling in tp53-deficient mantle cell lymphoma cell lines. Blood. 2014;124(21):5197-.
Sun Y, Luo D, Liao DJ. Cyclind1 protein plays different roles in modulating chemoresponses in mcf7 and mda-mb231 cells. J Carcinog. 2012;11:12.
Jirawatnotai S, Sittithumcharee G. Paradoxical roles of cyclin d1 in DNA stability. DNA Repair (Amst). 2016 Jun;42:56-62.
Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene. 2004 Jan 15;23(2):546-53.
Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, et al. Expression of cyclin d1a and d1b as predictive factors for treatment response in colorectal cancer. Br J Cancer. 2012 Nov 6;107(10):1684-91.
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Indonesian Journal of Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.